Harvard Bioscience (HBIO) Total Current Liabilities (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Total Current Liabilities data on file, last reported at $23.9 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $23.9 million, down 57.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.9 million (down 57.08% YoY), and the FY2025 annual result was $22.0 million, down 60.04% from the prior year.
• Total Current Liabilities advanced to $23.9 million in Q1 2026 per HBIO's latest filing, from $22.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $55.6 million in Q1 2025 and troughed at $21.4 million in Q3 2022.
• A 5-year average of $31.1 million and a median of $23.9 million in 2026 frame the typical range for Total Current Liabilities.
• On a YoY basis, Total Current Liabilities climbed as much as 144.03% in 2025 and fell as far as 60.04% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $23.2 million in 2022, then grew by 14.16% to $26.5 million in 2023, then jumped by 107.06% to $55.0 million in 2024, then sank by 60.04% to $22.0 million in 2025, then increased by 8.67% to $23.9 million in 2026.
• Business Quant data shows HBIO's Total Current Liabilities at $23.9 million in Q1 2026, $22.0 million in Q4 2025, and $54.4 million in Q3 2025.